Portopulmonary hypertension (PoPH) is a rare subtype of Group 1 pulmonary arterial
hypertension (PAH) with a poor prognosis. According to the most up-to-date definition, PoPH …

Portopulmonary hypertension (POPH) affects 5% to 6% of patients with advanced liver
disease and accounts for 5% to 15% of pulmonary arterial hypertension (PAH) cases …

Rationale: The population of patients with pulmonary arterial hypertension (PAH) has
evolved over time from predominantly young White women to an older, more racially diverse …

Objective To explore clinical characteristics, risk profiles, and outcomes of patients with
portopulmonary hypertension (PoPH) who have contraindications to liver transplant (LT) …

Disclosure Statement: The authors have no commercial or financial conflicts of interest
pertaining to the contents of this manuscript. AJ receives funding from the NIH …

Social determinants of health (SDoH) can impact the vulnerable pulmonary arterial
hypertension (PAH) population, especially during the COVID‐19 pandemic. Providers' …

Background Portopulmonary hypertension (PoPH), associated with increased mortality, can
limit treatment options for liver diseases. Data on the continuum of clinical risk related to …

Conflict of interest statements: Dr RJ Bernardo serves on the medical advisory board for
Janssen Pharmaceuticals. Dr VA de Jesus Perez has no conflict of interest to declare …

To better understand the impact of the COVID‐19 pandemic on the care of patients with
pulmonary hypertension, we conducted a retrospective cohort study evaluating health …

Cardio-pulmonary diseases, which were once regarded as a man's illness, have been one
of the leading causes of morbidity and mortality for both men and women in many countries …